Intravitreal injection of Aflibercept

DRUG6 trials

Sponsors

MMU Mullana Ambala, Stanford University, Innovent Biologics (Suzhou) Co. Ltd., Egypt health insurance, Suez Canal University Hospital

Conditions

Diabetic Macular EdemaExudative Age-related Macular DegenerationEye DiseasesNeovascular Age-related Macular Degeneration

Phase 1

Evaluation of IBI302 Injection in nAMD or DME

SuspendedNCT05961007

Innovent Biologics (Suzhou) Co. Ltd.Diabetic Macular Edema, Neovascular Age-related Macular Degeneration

Start: 2021-11-18End: 2024-04-30Target: 234Updated: 2023-07-27

Phase 3

Intravitreal injection versus medical treatment for acute CSR

Active, not recruitingPACTR202204601902304

Suez Canal University HospitalEye Diseases

Start: 2021-11-01Target: 45Updated: 2026-08-03

Phase 4

A clinical trial to study the effects of Aflibercept in patients with type 2 diabetes mellitus with reduced vision.

Active, not recruitingJPRN-UMIN000051561

MMU Mullana AmbalaDiabetic Macular Edema

Start: 2023-09-01Target: 100Updated: 2026-06-29

Unknown Phase

Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration

CompletedNCT01526070

Stanford UniversityExudative Age-related Macular Degeneration

Start: 2012-01-31End: 2014-07-31Updated: 2014-11-18

Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

CompletedNCT02000102

Stanford UniversityDiabetic Macular Edema

Start: 2013-09-30End: 2014-09-30Updated: 2014-11-18

Efficacy and safety of four-weeks versus twelve-weeks loading doses spacing of intravitreal Aflibercept for treatment of macular edema associated with Central Retinal Vein Occlusion

Active, not recruitingPACTR202201655513401

Egypt health insuranceEye Diseases

Start: 2022-03-01Target: 60Updated: 2026-08-03